
Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Dermatological Non-Steroidal Anti-Inflammatory Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Dermatological Non-Steroidal Anti-Inflammatory Drugs market include LEAD CHEMICAL, Merck KGaA, Verona Pharma, Arcutis, GlaxoSmithKline PLc, Huadong Medicine, Pfizer Inc., Roche and MSD, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Dermatological Non-Steroidal Anti-Inflammatory Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Dermatological Non-Steroidal Anti-Inflammatory Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Dermatological Non-Steroidal Anti-Inflammatory Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Dermatological Non-Steroidal Anti-Inflammatory Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Dermatological Non-Steroidal Anti-Inflammatory Drugs sales, projected growth trends, production technology, application and end-user industry.
Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Company
LEAD CHEMICAL
Merck KGaA
Verona Pharma
Arcutis
GlaxoSmithKline PLc
Huadong Medicine
Pfizer Inc.
Roche
MSD
Genzyme Co.
Shapuaisi
Sato Pharmaceutical
Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Type
Ketotifen
Ketoconazole
Phthalin Butan
Tacrolimus
Prednisone
Loratadine
Cyclosporine A
Others
Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Application
Hospital
Clinic
Others
Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Dermatological Non-Steroidal Anti-Inflammatory Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Dermatological Non-Steroidal Anti-Inflammatory Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Dermatological Non-Steroidal Anti-Inflammatory Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Dermatological Non-Steroidal Anti-Inflammatory Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dermatological Non-Steroidal Anti-Inflammatory Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatological Non-Steroidal Anti-Inflammatory Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Dermatological Non-Steroidal Anti-Inflammatory Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dermatological Non-Steroidal Anti-Inflammatory Drugs industry.
Chapter 3: Detailed analysis of Dermatological Non-Steroidal Anti-Inflammatory Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Dermatological Non-Steroidal Anti-Inflammatory Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Dermatological Non-Steroidal Anti-Inflammatory Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Dermatological Non-Steroidal Anti-Inflammatory Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Dermatological Non-Steroidal Anti-Inflammatory Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Dermatological Non-Steroidal Anti-Inflammatory Drugs market include LEAD CHEMICAL, Merck KGaA, Verona Pharma, Arcutis, GlaxoSmithKline PLc, Huadong Medicine, Pfizer Inc., Roche and MSD, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Dermatological Non-Steroidal Anti-Inflammatory Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Dermatological Non-Steroidal Anti-Inflammatory Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Dermatological Non-Steroidal Anti-Inflammatory Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Dermatological Non-Steroidal Anti-Inflammatory Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Dermatological Non-Steroidal Anti-Inflammatory Drugs sales, projected growth trends, production technology, application and end-user industry.
Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Company
LEAD CHEMICAL
Merck KGaA
Verona Pharma
Arcutis
GlaxoSmithKline PLc
Huadong Medicine
Pfizer Inc.
Roche
MSD
Genzyme Co.
Shapuaisi
Sato Pharmaceutical
Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Type
Ketotifen
Ketoconazole
Phthalin Butan
Tacrolimus
Prednisone
Loratadine
Cyclosporine A
Others
Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Application
Hospital
Clinic
Others
Dermatological Non-Steroidal Anti-Inflammatory Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Dermatological Non-Steroidal Anti-Inflammatory Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Dermatological Non-Steroidal Anti-Inflammatory Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Dermatological Non-Steroidal Anti-Inflammatory Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Dermatological Non-Steroidal Anti-Inflammatory Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatological Non-Steroidal Anti-Inflammatory Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dermatological Non-Steroidal Anti-Inflammatory Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatological Non-Steroidal Anti-Inflammatory Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Dermatological Non-Steroidal Anti-Inflammatory Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dermatological Non-Steroidal Anti-Inflammatory Drugs industry.
Chapter 3: Detailed analysis of Dermatological Non-Steroidal Anti-Inflammatory Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Dermatological Non-Steroidal Anti-Inflammatory Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Dermatological Non-Steroidal Anti-Inflammatory Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2020-2031)
- 1.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume (2020-2031)
- 1.2.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Dynamics
- 2.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Trends
- 2.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Drivers
- 2.3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Opportunities and Challenges
- 2.4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Industry Restraints
- 3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Company
- 3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Revenue Ranking in 2024
- 3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Revenue by Company (2020-2025)
- 3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Company (2020-2025)
- 3.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Average Price by Company (2020-2025)
- 3.5 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Ranking (2023-2025)
- 3.6 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Manufacturing Base and Headquarters
- 3.7 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Product Type and Application
- 3.8 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Dermatological Non-Steroidal Anti-Inflammatory Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Type
- 4.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Type Introduction
- 4.1.1 Ketotifen
- 4.1.2 Ketoconazole
- 4.1.3 Phthalin Butan
- 4.1.4 Tacrolimus
- 4.1.5 Prednisone
- 4.1.6 Loratadine
- 4.1.7 Cyclosporine A
- 4.1.8 Others
- 4.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type
- 4.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Type (2020-2031)
- 4.2.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Type (2020-2031)
- 4.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type
- 4.3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Type (2020-2031)
- 4.3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type (2020-2031)
- 5 Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Application
- 5.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application
- 5.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume by Application (2020-2031)
- 5.2.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Volume Share by Application (2020-2031)
- 5.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application
- 5.3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Application (2020-2031)
- 5.3.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application (2020-2031)
- 6 Dermatological Non-Steroidal Anti-Inflammatory Drugs Regional Sales and Value Analysis
- 6.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2020-2031)
- 6.2.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region: 2020-2025
- 6.2.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Region (2026-2031)
- 6.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region (2020-2031)
- 6.4.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region: 2020-2025
- 6.4.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Region (2026-2031)
- 6.5 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2020-2031)
- 6.6.2 North America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2020-2031)
- 6.7.2 Europe Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2020-2031)
- 6.9.2 South America Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Country, 2024 VS 2031
- 7 Dermatological Non-Steroidal Anti-Inflammatory Drugs Country-level Sales and Value Analysis
- 7.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2020-2031)
- 7.3.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2020-2025)
- 7.3.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales by Country (2026-2031)
- 7.4 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country (2020-2031)
- 7.4.1 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country (2020-2025)
- 7.4.2 Global Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.9.2 France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.16.2 China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.19.2 India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 LEAD CHEMICAL
- 8.1.1 LEAD CHEMICAL Comapny Information
- 8.1.2 LEAD CHEMICAL Business Overview
- 8.1.3 LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.1.4 LEAD CHEMICAL Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.1.5 LEAD CHEMICAL Recent Developments
- 8.2 Merck KGaA
- 8.2.1 Merck KGaA Comapny Information
- 8.2.2 Merck KGaA Business Overview
- 8.2.3 Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Merck KGaA Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.2.5 Merck KGaA Recent Developments
- 8.3 Verona Pharma
- 8.3.1 Verona Pharma Comapny Information
- 8.3.2 Verona Pharma Business Overview
- 8.3.3 Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Verona Pharma Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.3.5 Verona Pharma Recent Developments
- 8.4 Arcutis
- 8.4.1 Arcutis Comapny Information
- 8.4.2 Arcutis Business Overview
- 8.4.3 Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Arcutis Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.4.5 Arcutis Recent Developments
- 8.5 GlaxoSmithKline PLc
- 8.5.1 GlaxoSmithKline PLc Comapny Information
- 8.5.2 GlaxoSmithKline PLc Business Overview
- 8.5.3 GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.5.4 GlaxoSmithKline PLc Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.5.5 GlaxoSmithKline PLc Recent Developments
- 8.6 Huadong Medicine
- 8.6.1 Huadong Medicine Comapny Information
- 8.6.2 Huadong Medicine Business Overview
- 8.6.3 Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Huadong Medicine Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.6.5 Huadong Medicine Recent Developments
- 8.7 Pfizer Inc.
- 8.7.1 Pfizer Inc. Comapny Information
- 8.7.2 Pfizer Inc. Business Overview
- 8.7.3 Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Pfizer Inc. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.7.5 Pfizer Inc. Recent Developments
- 8.8 Roche
- 8.8.1 Roche Comapny Information
- 8.8.2 Roche Business Overview
- 8.8.3 Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Roche Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.8.5 Roche Recent Developments
- 8.9 MSD
- 8.9.1 MSD Comapny Information
- 8.9.2 MSD Business Overview
- 8.9.3 MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.9.4 MSD Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.9.5 MSD Recent Developments
- 8.10 Genzyme Co.
- 8.10.1 Genzyme Co. Comapny Information
- 8.10.2 Genzyme Co. Business Overview
- 8.10.3 Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Genzyme Co. Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.10.5 Genzyme Co. Recent Developments
- 8.11 Shapuaisi
- 8.11.1 Shapuaisi Comapny Information
- 8.11.2 Shapuaisi Business Overview
- 8.11.3 Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Shapuaisi Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.11.5 Shapuaisi Recent Developments
- 8.12 Sato Pharmaceutical
- 8.12.1 Sato Pharmaceutical Comapny Information
- 8.12.2 Sato Pharmaceutical Business Overview
- 8.12.3 Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Sato Pharmaceutical Dermatological Non-Steroidal Anti-Inflammatory Drugs Product Portfolio
- 8.12.5 Sato Pharmaceutical Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Value Chain Analysis
- 9.1.1 Dermatological Non-Steroidal Anti-Inflammatory Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Mode & Process
- 9.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Dermatological Non-Steroidal Anti-Inflammatory Drugs Distributors
- 9.2.3 Dermatological Non-Steroidal Anti-Inflammatory Drugs Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.